Mitsubishi Tanabe Pharma Corporation (4508) – Financial and Strategic SWOT Analysis Review

Mitsubishi Tanabe Pharma Corporation (4508) – Financial and Strategic SWOT Analysis Review Cover

Single Licence: $125

Buy Now
customer(s) bought this report
BUY WITH CONFIDENCE

Shopping on CFDMaster.com is Safe and Secure. GUARANTEED!
All information is encrypted and handled by PayPal.com

Need Assistance?
Have you got questions about this report? Why not speak to one of our advisors. Email us at business@cfdmaster.com or call us at +61 (02) 8011 3208
# Pages
Market
Country
Single User
Site License
Enterprisewide
61
Pharmaceuticals and Healthcare
Japan

  Mitsubishi Tanabe Pharma Corporation (4508) – Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and the potential opportunities and threats. The profile helps you formulate strategies that augment your business by enabling you to understand your partners, customers and competitors better.

The profile contains critical company information including:

– Business description – A detailed description of the company’s operations and business divisions.
– Corporate strategy – Analyst’s summarization of the company’s business strategy.
– SWOT Analysis – A detailed analysis of the company’s strengths, weakness, opportunities and threats.
– Company history – Progression of key events associated with the company.
– Major products and services – A list of major products, services and brands of the company.
– Key competitors – A list of key competitors to the company.
– Key employees – A list of the key executives of the company.
– Executive biographies – A brief summary of the executives’ employment history.
– Key operational heads – A list of personnel heading key departments/functions.
– Important locations and subsidiaries – A list and contact details of key locations and subsidiaries of the company.
– Key manufacturing facilities – A list of key manufacturing facilities of the company.
– Detailed financial ratios for the past five years – The latest financial ratios derived from the annual financial statements published by the company with 5 years history.
– Interim ratios for the last five interim periods – The latest financial ratios derived from the quarterly/semi-annual financial statements published by the company for 5 interims history.

Highlights

Mitsubishi Tanabe Pharma Corporation (Mitsubishi Tanabe), a subsidiary of Mitsubishi Chemical Holdings Corporation, is a pharmaceutical company. The company identifies, develops, manufactures, procures and commercializes ethical drugs and over-the-counter (OTC) pharmaceutical products. The company develops ethical drugs for autoimmune disease, diabetes and kidney diseases, central nervous system (CNS) diseases and others, and it also develops vaccines. The company major products include remicade, simponi, tenelia, ceredist and lexapro. Mitsubishi Tanabe major products include flucort f, nanpao, alegysal bien and okinazole. The company markets its products to wholesalers, hospitals, clinics, and drugstores. It also offers fine chemicals, information services, real-estate leasing and advertising, among others. The company along with its subsidiaries operates in Asia, Europe and North America. Mitsubishi Tanabe is headquartered in Chuo-ku, Osaka, Japan.

Mitsubishi Tanabe Pharma Corporation Key Recent Developments

Aug 02, 2016: Mitsubishi Tanabe Pharma Announces Financial Results for the First Three Months of the Fiscal year ending March 31, 2017
Jun 06, 2016: GHIT Fund Welcomes Ten New Partnerships With FUJIFILM, Otsuka, GSK, Johnson & Johnson, Kyowa Hakko Kirin, Merck, Mitsubishi Tanabe, Nipro, Sumitomo Dainippon Pharma and Salesforce.com
Jun 06, 2016: Mitsubishi Tanabe Pharma contribute funding to Global Health Innovative Technology Fund
Apr 01, 2016: MT Pharma Singapore Starts Business Operations Mitsubishi Tanabe Pharma’s Subsidiary in Singapore
Mar 29, 2016: Astellas and Mitsubishi Tanabe Pharma Execute Agreement for Share of Compound Libraries

Key benefits of buying this profile include:

You get detailed information about the company and its operations to identify potential customers and suppliers.
– The profile analyzes the company’s business structure, operations, major products and services, prospects, locations and subsidiaries, key executives and their biographies and key competitors.

Understand and respond to your competitors’ business structure and strategies, and capitalize on their weaknesses. Stay up to date on the major developments affecting the company.
– The company’s core strengths and weaknesses and areas of development or decline are analyzed and presented in the profile objectively. Recent developments in the company covered in the profile help you track important events.

Equip yourself with information that enables you to sharpen your strategies and transform your operations profitably.
– Opportunities that the company can explore and exploit are sized up and its growth potential assessed in the profile. Competitive and/or technological threats are highlighted.

Scout for potential investments and acquisition targets, with detailed insight into the companies’ strategic, financial and operational performance.
– Financial ratio presented for major public companies in the profile include the revenue trends, profitability, growth, margins and returns, liquidity and leverage, financial position and efficiency ratios.

Gain key insights into the company for academic or business research.
– Key elements such as SWOT analysis, corporate strategy and financial ratios and charts are incorporated in the profile to assist your academic or business research needs.

Note: Some sections may be missing if data is unavailable for the company

Request more information (Table of Contents, List of table, List of Figures) by using the form below:

Report Delivery

PDF SWOT Analysis Report An Electronic PDF copy of this Report will be sent to you via email.

Please allow up to 2 business days for the reports to arrive to your mailbox as some of our publishers prefer to send you the reports directly.

Purchase this Report today

Price: $125

Report Licences Explanation

* Single User: Electronic PDF copy delivered via email. Report can be used by individual purchaser only.

* Site License: Electronic PDF copy delivered via email. Report can be shared by unlimited users within one corporate location, e.g. a regional office.

* Enterprise Wide License: Electronic PDF copy delivered via email. Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company.

If you require a Site License or Enterprise Wide License please contact us to issue you an invoice.

Customers who Viewed this Report also Viewed

Risk warning: Your capital may be at risk. CFD trading is suitable for experienced traders and not beginners.